gilead sciences yeztugo - Search News

News

HIV, FDA and Gilead Sciences

The Jerusalem Post on MSN · 30m

FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,

BioPharma Dive · 2d

FDA approves twice-yearly shot of Gilead drug for HIV prevention

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.

Yahoo Finance · 2d

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg,

1d

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Fierce Pharma2d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results